Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1309P is a processed pseudogene of the U6 small nuclear RNA gene family. Pseudogenes are genomic DNA sequences similar to normal genes but typically nonfunctional; they arise mainly via reverse transcription and integration of RNA transcripts back into the genome. U6 small nuclear RNA is an essential RNA component of the spliceosome, required for the removal of introns from precursor mRNA by splicing[3][7]. The pseudogenes of U6, including RNU6-1309P, do not function in mRNA processing, do not appear to have roles in normal physiology or disease, and are not therapeutic targets. Their presence is a marker of retrotransposition activity in genomes but has no known direct clinical, pharmacological, or mechanistic action[1][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1309, pseudogene (RNU6-1309P).